**Sir,**

To our knowledge, [@bib3], [@bib2]) twice reported in 2013 the only animal model of sinusoidal obstruction syndrome (SOS) induced by FOLFOX (oxaliplatin, 5-fluoro-uracyl, folinic acid) administration. In this model, intraperitoneal FOLFOX administration had consistently induced SOS in 21 mice ([@bib3], [@bib2]).

Prior to implementing a study in our institutional laboratory, we checked the reproducibility of [@bib3], [@bib2]) procedures. Experiments were approved by the Veterinary Office of our university and carried out in accordance with institutional animal care guidelines. In line with [@bib3], 10 C57BL/6 mice (Janvier Laboratory, Le Genest-Saint-Isle, France) between 8 and 10 weeks of age were housed in the animal facility of our hospital, had unrestricted access to standard diet (Global rodent diet-2016, Harlan Laboratories, Madison, WI, USA) and water, were maintained on a 12 h light/darkness cycle at a controlled room temperature (21±2 °C) and humidity (between 40 and 60%), and had an acclimation period of 1 week. Intraperitoneal oxaliplatin (Eloxatine, Sanofi-Aventis Laboratory, Gentilly, France) 6 mg kg^−1^, followed 2 h later by 5-fluoro-uracyl (Fluorouracile Meram, Coopération Pharmaceutique Française, Melun, France) 50 mg kg^−1^, and folinic acid (Elvorine, Wyeth-Lederle, Catania, Italia) 90 mg kg^−1^, were prepared immediately before use and injected intraperitoneally in a volume of 250 ml, during the light cycle, on a weekly basis, for 5 weeks ([@bib3]). One week after the final dose, hepatectomy was carried out under isoflurane inhalation anaesthesia.

One mouse died. Liver tissue was immersion-fixed in 4% buffered formaldehyde, embedded in paraffin, sectioned and stained with hematoxylin--eosin and Sirius red using standard histological techniques ([@bib3]). Liver sections did not display any steatosis, inflammation, sinusoidal dilatation, perisinusoidal fibrosis, fibrotic venular occlusion or disrupted hepatocellular morphology that would be characteristic of any parenchyma alteration including SOS.

SOS is frequently observed on the healthy remnant parenchyma in patients undergoing liver resection for colorectal cancer metastasis as a side effect of FOLFOX chemotherapy ([@bib4]). An animal model allowing SOS to be investigated independently of the effect of any confounding factors was deemed necessary. The present investigation of identical C57BL/6 mice, receiving an identical intraperitoneal chemotherapy regimen over an identical time duration, as reported by [@bib3], [@bib2]) to have consistently induced SOS, failed to induce SOS in any mice. Diet alters only steatotic changes in the liver and does not alter SOS features ([@bib5]). Only a diet, specifically deficient in one or more of the essential amino acids, limits monocrotaline-induced SOS in rats ([@bib1]). [@bib3], [@bib2]) did not administer such a diet.

In contrast with previously reported ([@bib3], [@bib2]), intraperitoneal FOLFOX does not consistently induce SOS in C57BL/6 mice. The discrepancy between our results and the results reported twice by [@bib3], [@bib2]) must be taken into account prior to implementing SOS investigation in a mouse model.
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